Bio-Techne Corporation (NASDAQ:TECH) is one of the . On July 9, TD Cowen analyst Daniel Brennan initiated a new Buy rating on Bio-Techne Corporation (NASDAQ:TECH) with a $65 price target. A team of scientists wearing lab coats and protective eyewear in a research laboratory, intently looking into microscopes and analyzing results. The analyst told investors that Bio-Techne Corporation (NASDAQ:TECH) has potential for margin expansion and strong organic growth, and believes that the company’s current valuation is undervalued and fails to accurately show its robust growth opportunities in high-demand areas of life science tools. Brennan added that despite the macroeconomic risks affecting the company, Bio-Techne Corporation (NASDAQ:TECH) has a solid portfolio that is primarily focused on consumables and is highly regarded by customers, positioning it well to outperform its peers. He thus believes that the consensus growth targets for FY26 are reasonable, particularly following a year of downward revisions. The analyst also expects margin recovery with the scaling of mergers and acquisitions and improvement in market conditions. Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that provides innovative tools and bioactive reagents for the research and clinical diagnostic communities. Its operations are divided into the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment is involved in the manufacture and development of purified proteins and reagent solutions, while the Diagnostics and Genomics segment develops and manufactures diagnostic products. While we acknowledge the potential of TECH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TECH and that has 100x upside potential, check out our report about this . Bio-Techne Corporation (TECH): A Bull Case TheoryBio-Techne, USP Partner to Enhance Monoclonal Antibody, Gene Therapy Development... Insider Monkey Quarterly Strategy 300% 200% 100% Returns since its inception in May 2014 (through February 19th, 2025) Hedge Fund Resource Center Billionaire Hedge Funds Warren Buffett Berkshire Hathaway $293,447,417,000 David Einhorn Greenlight Capital $1,491,303,000 George Soros Soros Fund Management $5,416,602,000 Jim Simons Renaissance Technologies $77,426,184,000 Leon Cooperman Omega Advisors $1,886,381,000 Carl Icahn Icahn Capital LP $22,521,664,000 Steve Cohen Point72 Asset Management $22,767,998,000 John Paulson Paulson & Co $3,510,256,000 David Tepper Appaloosa Management LP $4,198,712,000 Paul Tudor Jones Tudor Investment Corp $6,160,740,000 AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Bio-Techne Corporation (TECH) Gets Initiated With a New Buy Rating at TD Cowen

TD Cowen analyst Daniel Brennan initiated a Buy rating on Bio-Techne Corporation (NASDAQ:TECH) with a $65 price target, citing undervaluation and growth potential in life science tools. The analyst highlights the company's strong portfolio, margin expansion prospects, and resilience amid macroeconomic risks.